Sellas CEO Reaffirms Confidence in Phase 3 Regal Trial Amidst Market Volatility
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 27 2026
0mins
Should l Buy SLS?
Source: stocktwits
- Confidence in Regal Trial: Sellas Life Sciences CEO Angelos Stergiou expressed steadfast confidence in the commercial prospects of the Regal trial despite its blinded status, with final analysis expected after 80 overall survival events are recorded, which could enhance the company's market position in acute myeloid leukemia (AML).
- SLS009 Clinical Updates: Stergiou highlighted 2026 as a pivotal year for the CDK9 inhibitor SLS009, urging investors to look for clinical updates and top-line data from ongoing Phase 2 studies this year, with recent lab findings indicating promising effects in hard-to-treat AML cases, potentially boosting the company's future market performance.
- Equity Incentive Plan Expansion: Stergiou is seeking approval to increase the share reserve under the 2023 Amended Equity Incentive Plan by 20 million shares, as only 7,991 shares remain available for future awards, and approval would facilitate executive incentives and attract more investor interest in the company's long-term growth.
- Institutional Investor Participation: Ahead of expected clinical milestones, BlackRock disclosed a 6.8% stake in Sellas, indicating growing confidence among institutional investors, while Dagco increased its holdings by 78%, further solidifying Sellas's appeal in the healthcare investment landscape.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SLS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SLS
Wall Street analysts forecast SLS stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 5.010
Low
7.00
Averages
7.25
High
7.50
Current: 5.010
Low
7.00
Averages
7.25
High
7.50
About SLS
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of therapeutics for a range of cancer indications. The Company's product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GPS is a cancer immunotherapeutic agent licensed by Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed by GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau, and Taiwan.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sellas Awaits Phase 3 AML Trial Data Amid Analyst Optimism
- Clinical Trial Progress: Sellas' Phase 3 REGAL trial is evaluating its therapy for acute myeloid leukemia (AML), having reported 72 events and nearing the critical threshold of 80 events needed for final analysis, which could significantly impact the company's future treatment options.
- Earnings Expectations: Analysts anticipate that Sellas will report a Q1 loss of $0.06 per share on Tuesday, slightly wider than the previous quarter's loss of $0.05, yet the company has beaten Wall Street estimates for seven consecutive quarters, indicating strong long-term potential.
- Market Sentiment Shift: While retail sentiment on Stocktwits remains in the 'bearish' zone, message volume has surged nearly 50%, reflecting increased attention on Sellas, with some users expressing optimism about the prospects of its GPS therapy.
- Short Interest Surge: Sellas' short interest has climbed to 30.7%, the highest level since 2018, as investors brace for key trial data and earnings reports, which could lead to significant stock price volatility.
See More
Deutsche Bank Increases Sellas Stake by 50%
- Stake Increase: Deutsche Bank raised its stake in Sellas Life Sciences by 50% during the March quarter, adding 45,958 shares to reach a total of 137,646 shares valued at $582,000, indicating strong confidence in the company's future potential.
- Shareholder Composition: Major shareholders of Sellas include Vanguard Group with 8.47 million shares valued at $31.9 million, BlackRock with 7.54 million shares valued at $28.4 million, and State Street with a stake worth $6 million, providing a robust financial backing for the company.
- Financial Outlook: Analysts expect Sellas to report another loss-making quarter with an estimated EPS of $0.06, widening from a loss of $0.05 in the previous quarter, while EBIT is projected to increase from $8.3 million to $9 million, reflecting ongoing investments in clinical development.
- AML Trial Progress: Sellas' Phase 3 Regal study is evaluating Galinpepimut-S as a maintenance therapy for AML patients, approaching the 80 overall-survival-event threshold required for topline analysis, showcasing the company's proactive advancements in drug development.
See More
Sellas Life Sciences Engages in EU Biotech Policy Talks
- Stock Price Increase: Shares of Sellas Life Sciences Group, Inc. (SLS) rose 2% on Monday, closing above the $5 mark after a two-week dip, reflecting investor optimism regarding the company's constructive dialogue with European lawmakers.
- AML Trial Progress: The ongoing Phase 3 Regal trial has recorded 72 survival events, nearing the 80-event threshold required for topline analysis, indicating the company's potential in cancer treatment as it prepares for database lock and statistical analysis.
- Shareholder Plan Expansion: Sellas is seeking shareholder approval to expand its 2023 Amended and Restated Equity Incentive Plan by 20 million shares, aiming to replenish its stock-based compensation pool, which currently has only 7,991 shares available for future awards, thus enhancing talent attraction and retention.
- Strategic Policy Dialogue: CEO Stergiou described the discussions with the EU Public Health Committee as “exceptionally constructive,” emphasizing the company's contributions to the Biotech Act, which may enhance market access and competitiveness, positioning Sellas favorably for future growth opportunities.
See More
Sellas Proposes 20 Million Share Incentive Expansion Amid Regal Trial Progress
- Shareholder Vote Focus: Sellas Life Sciences is holding a shareholder vote on a proposal to expand its 2023 Amended Equity Incentive Plan by 20 million shares, with CEO Angelos Stergiou urging support while investors express dilution concerns.
- Survival Event Progress: As of December 26, the Regal trial recorded 72 overall-survival events, nearing the 80-event threshold required for topline analysis, suggesting patients may be living longer than initially expected, which could positively impact trial outcomes.
- Dilution Concerns Intensify: Retail investors have voiced concerns about the proposed equity plan potentially causing about 20% dilution, especially ahead of the Phase 3 data release, with around 70% of respondents in a poll indicating opposition to the proposal.
- AML Pipeline Remains in Focus: Despite dilution debates, investors are closely monitoring upcoming milestones in the company’s acute myeloid leukemia (AML) programs, with clinical updates and topline data for the CDK9 inhibitor SLS009 expected in 2026.
See More
Markets Retreat as Investors Await Fed Decision and Big Tech Earnings
- Cautious Market Sentiment: U.S. stock futures retreated from record highs as investors tread carefully ahead of the Fed's rate decision and major tech earnings, with Nasdaq futures down 0.5% and S&P 500 futures slipping 0.3%.
- Geopolitical Impact: Renewed tensions in the Middle East have driven Brent crude prices above $110, reflecting market concerns over supply disruptions, while gold has slipped to a three-week low, indicating mixed safe-haven positioning among investors.
- Tech Stock Dynamics: Retail sentiment towards the SPDR S&P 500 ETF (SPY) has shifted back to 'bullish', while the Invesco QQQ Trust (QQQ) remains 'bearish', highlighting a divergence in market sentiment as the tech sector approaches a critical earnings period.
- Stocks to Watch: Nvidia (NVDA) has reached a new high driven by AI momentum, solidifying its position as the world's most valuable company, while Bed Bath & Beyond (BBBY) is trending after reporting its first quarterly revenue growth in five years, attracting retail interest.
See More
Sellas Life Sciences Increases Stake and Seeks Shareholder Approval
- Stake Increase: Commonwealth Equity Services raised its stake in Sellas Life Sciences by 32%, adding 9,226 shares to total holdings of 38,470 shares valued at approximately $162,730, indicating strong confidence in the company's cancer drug development.
- CEO Reaffirms Confidence: CEO Angelos Stergiou stated that his confidence in the commercial potential of the REGAL trial remains unchanged despite the trial being blinded, with expectations for database lock and statistical analysis once 80 overall survival events are recorded.
- Shareholder Plan Expansion: Sellas is seeking shareholder approval to increase its share reserve under the 2023 Amended Equity Incentive Plan by 20 million shares, addressing the limited availability of only 7,991 shares for future awards under the existing plan.
- Positive Market Sentiment: On Stocktwits, retail sentiment for SLS is deemed 'bullish', with users expressing confidence that institutional players like BlackRock will support the shareholder plan, reflecting strong market optimism towards Sellas.
See More
Sellas Awaits Phase 3 AML Trial Data Amid Analyst Optimism
- Clinical Trial Progress: Sellas' Phase 3 REGAL trial is evaluating its therapy for acute myeloid leukemia (AML), having reported 72 events and nearing the critical threshold of 80 events needed for final analysis, which could significantly impact the company's future treatment options.
- Earnings Expectations: Analysts anticipate that Sellas will report a Q1 loss of $0.06 per share on Tuesday, slightly wider than the previous quarter's loss of $0.05, yet the company has beaten Wall Street estimates for seven consecutive quarters, indicating strong long-term potential.
- Market Sentiment Shift: While retail sentiment on Stocktwits remains in the 'bearish' zone, message volume has surged nearly 50%, reflecting increased attention on Sellas, with some users expressing optimism about the prospects of its GPS therapy.
- Short Interest Surge: Sellas' short interest has climbed to 30.7%, the highest level since 2018, as investors brace for key trial data and earnings reports, which could lead to significant stock price volatility.
See More
Deutsche Bank Increases Sellas Stake by 50%
- Stake Increase: Deutsche Bank raised its stake in Sellas Life Sciences by 50% during the March quarter, adding 45,958 shares to reach a total of 137,646 shares valued at $582,000, indicating strong confidence in the company's future potential.
- Shareholder Composition: Major shareholders of Sellas include Vanguard Group with 8.47 million shares valued at $31.9 million, BlackRock with 7.54 million shares valued at $28.4 million, and State Street with a stake worth $6 million, providing a robust financial backing for the company.
- Financial Outlook: Analysts expect Sellas to report another loss-making quarter with an estimated EPS of $0.06, widening from a loss of $0.05 in the previous quarter, while EBIT is projected to increase from $8.3 million to $9 million, reflecting ongoing investments in clinical development.
- AML Trial Progress: Sellas' Phase 3 Regal study is evaluating Galinpepimut-S as a maintenance therapy for AML patients, approaching the 80 overall-survival-event threshold required for topline analysis, showcasing the company's proactive advancements in drug development.
See More
Sellas Life Sciences Engages in EU Biotech Policy Talks
- Stock Price Increase: Shares of Sellas Life Sciences Group, Inc. (SLS) rose 2% on Monday, closing above the $5 mark after a two-week dip, reflecting investor optimism regarding the company's constructive dialogue with European lawmakers.
- AML Trial Progress: The ongoing Phase 3 Regal trial has recorded 72 survival events, nearing the 80-event threshold required for topline analysis, indicating the company's potential in cancer treatment as it prepares for database lock and statistical analysis.
- Shareholder Plan Expansion: Sellas is seeking shareholder approval to expand its 2023 Amended and Restated Equity Incentive Plan by 20 million shares, aiming to replenish its stock-based compensation pool, which currently has only 7,991 shares available for future awards, thus enhancing talent attraction and retention.
- Strategic Policy Dialogue: CEO Stergiou described the discussions with the EU Public Health Committee as “exceptionally constructive,” emphasizing the company's contributions to the Biotech Act, which may enhance market access and competitiveness, positioning Sellas favorably for future growth opportunities.
See More
Sellas Proposes 20 Million Share Incentive Expansion Amid Regal Trial Progress
- Shareholder Vote Focus: Sellas Life Sciences is holding a shareholder vote on a proposal to expand its 2023 Amended Equity Incentive Plan by 20 million shares, with CEO Angelos Stergiou urging support while investors express dilution concerns.
- Survival Event Progress: As of December 26, the Regal trial recorded 72 overall-survival events, nearing the 80-event threshold required for topline analysis, suggesting patients may be living longer than initially expected, which could positively impact trial outcomes.
- Dilution Concerns Intensify: Retail investors have voiced concerns about the proposed equity plan potentially causing about 20% dilution, especially ahead of the Phase 3 data release, with around 70% of respondents in a poll indicating opposition to the proposal.
- AML Pipeline Remains in Focus: Despite dilution debates, investors are closely monitoring upcoming milestones in the company’s acute myeloid leukemia (AML) programs, with clinical updates and topline data for the CDK9 inhibitor SLS009 expected in 2026.
See More
Markets Retreat as Investors Await Fed Decision and Big Tech Earnings
- Cautious Market Sentiment: U.S. stock futures retreated from record highs as investors tread carefully ahead of the Fed's rate decision and major tech earnings, with Nasdaq futures down 0.5% and S&P 500 futures slipping 0.3%.
- Geopolitical Impact: Renewed tensions in the Middle East have driven Brent crude prices above $110, reflecting market concerns over supply disruptions, while gold has slipped to a three-week low, indicating mixed safe-haven positioning among investors.
- Tech Stock Dynamics: Retail sentiment towards the SPDR S&P 500 ETF (SPY) has shifted back to 'bullish', while the Invesco QQQ Trust (QQQ) remains 'bearish', highlighting a divergence in market sentiment as the tech sector approaches a critical earnings period.
- Stocks to Watch: Nvidia (NVDA) has reached a new high driven by AI momentum, solidifying its position as the world's most valuable company, while Bed Bath & Beyond (BBBY) is trending after reporting its first quarterly revenue growth in five years, attracting retail interest.
See More
Sellas Life Sciences Increases Stake and Seeks Shareholder Approval
- Stake Increase: Commonwealth Equity Services raised its stake in Sellas Life Sciences by 32%, adding 9,226 shares to total holdings of 38,470 shares valued at approximately $162,730, indicating strong confidence in the company's cancer drug development.
- CEO Reaffirms Confidence: CEO Angelos Stergiou stated that his confidence in the commercial potential of the REGAL trial remains unchanged despite the trial being blinded, with expectations for database lock and statistical analysis once 80 overall survival events are recorded.
- Shareholder Plan Expansion: Sellas is seeking shareholder approval to increase its share reserve under the 2023 Amended Equity Incentive Plan by 20 million shares, addressing the limited availability of only 7,991 shares for future awards under the existing plan.
- Positive Market Sentiment: On Stocktwits, retail sentiment for SLS is deemed 'bullish', with users expressing confidence that institutional players like BlackRock will support the shareholder plan, reflecting strong market optimism towards Sellas.
See More
